Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Table of Contents

August 01, 2017; Volume 362,Issue 2

Minireviews

  • You have access
    Pleiotropic and Adverse Effects of Statins—Do Epigenetics Play a Role?
    Stephanie C. Allen and Cyril D.S. Mamotte
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 319-326; DOI: https://doi.org/10.1124/jpet.117.242081

Behavioral Pharmacology

  • You have access
    TRV0109101, a G Protein-Biased Agonist of the µ-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic Administration
    Michael Koblish, Richard Carr, Edward R. Siuda, David H. Rominger, William Gowen-MacDonald, Conrad L. Cowan, Aimee L. Crombie, Jonathan D. Violin and Michael W. Lark
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 254-262; DOI: https://doi.org/10.1124/jpet.117.241117
  • You have access
    Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys
    Lenka Hruba and Lance R. McMahon
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 278-286; DOI: https://doi.org/10.1124/jpet.117.240572
  • You have access
    Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice
    Ai-Ling Li, Lawrence M. Carey, Ken Mackie and Andrea G. Hohmann
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 296-305; DOI: https://doi.org/10.1124/jpet.117.241901

Cardiovascular

  • S1P receptor 1-Mediated Anti–Renin-Angiotensin System Cardioprotection: Pivotal Role of Mast Cell Aldehyde Dehydrogenase Type 2
    You have access
    S1P receptor 1-Mediated Anti–Renin-Angiotensin System Cardioprotection: Pivotal Role of Mast Cell Aldehyde Dehydrogenase Type 2
    Alice Marino, Takuya Sakamoto, Pablo A. Robador, Kengo Tomita and Roberto Levi
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 230-242; DOI: https://doi.org/10.1124/jpet.117.241976

Cellular and Molecular

  • You have access
    Anti-Psoriatic Drug Monomethylfumarate Increases Nuclear Factor Erythroid 2-Related Factor 2 Levels and Induces Aquaporin-3 mRNA and Protein Expression
    Inas Helwa, Vivek Choudhary, Xunsheng Chen, Ismail Kaddour-Djebbar and Wendy B. Bollag
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 243-253; DOI: https://doi.org/10.1124/jpet.116.239715

Chemotherapy, Antibiotics, and Gene Therapy

  • You have access
    Carboxyamidotriazole Synergizes with Sorafenib to Combat Non–Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis
    Chen Chen, Rui Ju, Jing Shi, Wei Chen, Fangrui Sun, Lei Zhu, Juan Li, Dechang Zhang, Caiying Ye and Lei Guo
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 219-229; DOI: https://doi.org/10.1124/jpet.117.240986
  • Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
    You have access
    Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
    Andrea Henrich, Markus Joerger, Stefanie Kraff, Ulrich Jaehde, Wilhelm Huisinga, Charlotte Kloft and Zinnia Patricia Parra-Guillen
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 347-358; DOI: https://doi.org/10.1124/jpet.117.240309

Drug Discovery and Translational Medicine

  • In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist
    Open Access
    In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist
    Carsten Theodor Beuckmann, Michiyuki Suzuki, Takashi Ueno, Kazuya Nagaoka, Tohru Arai and Hiroyuki Higashiyama
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 287-295; DOI: https://doi.org/10.1124/jpet.117.241422
  • You have access
    Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31
    Lita A. Freeman, Stephen J. Demosky, Monika Konaklieva, Rostislav Kuskovsky, Angel Aponte, Alice F. Ossoli, Scott M. Gordon, Ross F. Koby, Kelly A. Manthei, Min Shen, Boris L. Vaisman, Robert D. Shamburek, Ajit Jadhav, Laura Calabresi, Marjan Gucek, John J.G. Tesmer, Rodney L. Levine and Alan T. Remaley
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 306-318; DOI: https://doi.org/10.1124/jpet.117.240457
  • Open Access
    Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2
    Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705
  • Open Access
    Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development
    Scott L. Harbeson, Adam J. Morgan, Julie F. Liu, Ara M. Aslanian, Sophia Nguyen, Gary W. Bridson, Christopher L. Brummel, Lijun Wu, Roger D. Tung, Lana Pilja, Virginia Braman and Vinita Uttamsingh
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 359-367; DOI: https://doi.org/10.1124/jpet.117.241497

Inflammation, Immunopharmacology, and Asthma

  • Open Access
    Route of Administration Affects Corticosteroid Sensitivity of a Combined Ovalbumin and Lipopolysaccharide Model of Asthma Exacerbation in Guinea Pigs
    Alexander P. P. Lowe, Rhian S. Thomas, Anthony T. Nials, Emma J. Kidd, Kenneth J. Broadley and William R. Ford
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 327-337; DOI: https://doi.org/10.1124/jpet.117.241927

Metabolism, Transport, and Pharmacogenomics

  • You have access
    Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin
    Emanuela Salvatorelli, Pierantonio Menna, Massimo Chello, Elvio Covino and Giorgio Minotti
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 263-270; DOI: https://doi.org/10.1124/jpet.117.242388
  • You have access
    Potential Drug Interactions Mediated by Renal Organic Anion Transporter OATP4C1
    Toshihiro Sato, Eikan Mishima, Nariyasu Mano, Takaaki Abe and Hiroaki Yamaguchi
    Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 271-277; DOI: https://doi.org/10.1124/jpet.117.241703
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics: 362 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 362, Issue 2
1 Aug 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Minireviews
  • Behavioral Pharmacology
  • Cardiovascular
  • Cellular and Molecular
  • Chemotherapy, Antibiotics, and Gene Therapy
  • Drug Discovery and Translational Medicine
  • Inflammation, Immunopharmacology, and Asthma
  • Metabolism, Transport, and Pharmacogenomics
  • Most Cited
  • Most Read
Loading
  • Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
  • Functional Selectivity and Classical Concepts of Quantitative Pharmacology
  • Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
  • The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data
  • A METHOD FOR DETERMINING LOSS OF PAIN SENSATION
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics